I remain upbeat about the shares of Intuitive Surgical (ISRG), a US-based designer, manufacturer and marketer of robotic-assisted surgical systems. Recently, the company announced certain unaudited preliminary fourth quarter and full year 2016 results. In 2016, approximately 753,000 surgical procedures were performed with the da Vinci Surgical System, up approximately 15% y-o-y. The improvement was driven by the growth in US general surgery procedures and worldwide urologic procedures. In the fourth quarter of 2016, da Vinci procedures increased also 15% y-o-y. Intuitive Surgical expects total da Vinci procedures to grow 9-12% in 2017.The company expects revenues for the fourth quarter of 2016 of approximately $757 mn, an increase of 12% from the year-ago quarter. For full year 2016, revenues are estimated at $2.7 bn, up 13% y-o-y. I believe that the growing adoption of Intuitive Surgical’s da Vinci system among physicians for general surgery, oncology, urology and gynecology procedures is a key growth catalyst. Moreover, increasing procedural volumes outside the US present significant growth opportunities for the company.Intuitive Surgical plans to report Q4 and 2016 results on Jan 24, after the closing bell. To note, the company posted a positive earnings surprise of 17.86% over the last four quarters, and I believe that this time, it will be able to positively surprise investors again.I expect Intuitive Surgical’s shares to continue to rebound. Medium-term target is $740. $ISRG, Intuitive Surgical, Inc. / D